Flu season may not boost better vaccine

NEW YORK, Feb. 5 (UPI) -- It's unclear if the severity of the current U.S. flu season will translate into larger investment in vaccines, analysts say.

Geologists turn to unmanned aircraft

LAKEWOOD, Colo., Dec. 30 (UPI) -- The U.S. Geological Survey is turning to unmanned aircraft for a closer look at volcanoes, wildfires and remote areas of the world, officials said.

Lilly moves on from Prozac to Cymbalta

INDIANAPOLIS, Aug. 23 (UPI) -- Eli Lilly and Co., based in Indiana, has overcome the loss of revenue when its blockbuster drug Prozac went off-patent nine years ago, company officials said.

Soap star Pinter beats oral cancer

NEW YORK, Oct. 26 (UPI) -- U.S. soap opera actress Colleen Zenk Pinter has won her battle with oral cancer after undergoing three operations, CBS reported.

Analysis: J&J acquires Pfizer's OTC unit

WASHINGTON, June 26 (UPI) -- Johnson and Johnson's decision to purchase Pfizer's consumer division for $16.6 billion is a positive for Pfizer, but analysts said it probably won't haveo much of an impact on the nonprescription products field.
STEVE MITCHELL, UPI Senior Medical Correspondent

Analysis: Pfizer's exit may kill indiplon

WASHINGTON, June 23 (UPI) -- Pfizer's decision to end its deal to develop indiplon will have negative consequences for Neurocrine and could spell the end for the sleep aid that was at one time a much-heralded prospect.
STEVE MITCHELL, UPI Senior Medical Correspondent

Analysis: GSK to purchase Pfizer unit?

WASHINGTON, June 2 (UPI) -- GlaxoSmithKline reportedly is looking to buy Pfizer's consumer healthcare division for $15 billion, a price tag analysts say will likely make it the highest bidder.
STEVE MITCHELL, UPI Senior Medical Correspondent